Literature DB >> 21927835

Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Margareeta Häkkinen1, Terhi Launiainen, Erkki Vuori, Ilkka Ojanperä.   

Abstract

BACKGROUND: Although buprenorphine therapy has proved to be successful in opioid maintenance treatments, the drug is also widely abused in many countries by intravenous injection or sniffing ("snorting"). In Finland, buprenorphine is the most important abused opioid causing fatal poisonings.
PURPOSE: To evaluate the drug and alcohol findings as well as the cause and manner of death in all buprenorphine-related post-mortem cases for the age group 14-44 years in Finland from 2000 to 2008.
METHOD: This was a retrospective analysis of data on opioid-associated deaths in the Finnish comprehensive postmortem toxicology database based on medico-legal autopsies, case background information and laboratory analyses.
RESULTS: Buprenorphine was found in 29% of all 1,363 opioid-positive cases, and buprenorphine poisoning was the cause of death in 182 cases out of 391 buprenorphine-positive cases (47%). In these fatal poisonings, the blood buprenorphine/norbuprenorphine concentration ratio was significantly higher than in cases with other causes of death. The manner of death in buprenorphine poisonings that were almost exclusively accidental differed significantly from other buprenorphine-related cases, which also involved diseases and suicides. Death was immediate in 10% of fatal buprenorphine poisonings, was delayed, during sleep, in 52%, and followed an unknown course of events in 38%. In immediate poisonings, the median blood buprenorphine concentration (3.0 μg/l) was significantly higher than that in delayed poisonings (1.2 μg/l). In most buprenorphine poisonings (92%), no opioids other than buprenorphine were involved, but benzodiazepines and alcohol were found in 82 and 58% of cases, respectively. The median concentrations of opioids and benzodiazepines in buprenorphine poisonings were in the therapeutic range. Only one fatal poisoning was found in which neither alcohol nor drugs other than buprenorphine were found.
CONCLUSION: A fatal buprenorphine poisoning is typically accidental, and the average victim is a 27-year-old male addict. Circumstantial and environmental factors seem to be crucial in determining the outcome of the poisoning.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21927835     DOI: 10.1007/s00228-011-1122-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  46 in total

1.  Screening for basic drugs in 2-mL urine samples by dual-plate overpressured layer chromatography and comparison with gas chromatography-mass spectrometry.

Authors:  Anna Pelander; Ilkka Ojanperä; Johanna Sistonen; Ilpo Rasanen; Erkki Vuori
Journal:  J Anal Toxicol       Date:  2003 May-Jun       Impact factor: 3.367

Review 2.  Mechanisms of fatal opioid overdose.

Authors:  J M White; R J Irvine
Journal:  Addiction       Date:  1999-07       Impact factor: 6.526

3.  Surveillance of injury-related deaths: medicolegal autopsy rates and trends in Finland.

Authors:  Philippe Lunetta; Anne Lounamaa; Sanna Sihvonen
Journal:  Inj Prev       Date:  2007-08       Impact factor: 2.399

4.  Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients.

Authors:  Mauri Aalto; Jukka-Pekka Visapää; Jukka T Halme; Carola Fabritius; Mikko Salaspuro
Journal:  Nord J Psychiatry       Date:  2010-11-03       Impact factor: 2.202

5.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

Review 7.  Benzodiazepines, methadone and buprenorphine: interactions and clinical management.

Authors:  Nicholas Lintzeris; Suzanne Nielsen
Journal:  Am J Addict       Date:  2010 Jan-Feb

8.  Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.

Authors:  Suzanne Nielsen; Paul Dietze; Nicole Lee; Adrian Dunlop; David Taylor
Journal:  Addiction       Date:  2007-02-06       Impact factor: 6.526

9.  A new series of 13 buprenorphine-related deaths.

Authors:  Pascal Kintz
Journal:  Clin Biochem       Date:  2002-10       Impact factor: 3.281

10.  Six deaths linked to concomitant use of buprenorphine and benzodiazepines.

Authors:  M Reynaud; G Petit; D Potard; P Courty
Journal:  Addiction       Date:  1998-09       Impact factor: 6.526

View more
  29 in total

Review 1.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

2.  Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012.

Authors:  Stefanie Iwersen-Bergmann; Hilke Jungen; Hilke Andresen-Streichert; Alexander Müller; Sally Elakkary; Klaus Püschel; Axel Heinemann
Journal:  Int J Legal Med       Date:  2014-05-25       Impact factor: 2.686

3.  Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Authors:  Ines Derbel; Asma Ghorbel; Férièle Messadi Akrout; Abdelmajid Zahaf
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

4.  The effect of banning MDPV on the incidence of MDPV-positive findings among users of illegal drugs and on court decisions in traffic cases in Finland.

Authors:  Pirkko Kriikku; Janne Rintatalo; Katja Pihlainen; Jukka Hurme; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2015-04-02       Impact factor: 2.686

Review 5.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

6.  Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.

Authors:  Walid F Gellad; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Florentina E Sileanu; John P Cashy; Maria Mor; Jennifer A Hale; Thomas Radomski; Leslie R M Hausmann; Michael J Fine; Chester B Good
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

7.  Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-07       Impact factor: 2.007

8.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

9.  Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Authors:  Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese
Journal:  Drug Alcohol Depend       Date:  2013-05-18       Impact factor: 4.492

Review 10.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.